FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1805348119> ?p ?o ?g. }

• W1805348119 abstract "Abstract Background Since tacrolimus ointment was approved by the U.S. Food and Drug Administration (FDA) as a promising treatment for atopic dermatitis, it has been approved in more than 30 additional countries, including numerous European Union member nations. Moreover, in the current clinical routine the use of this drug is no longer restricted to the approved indication, but has been extended to a wide variety of inflammatory skin diseases including some with the potential of malignant transformation. So far, the side-effects reported from the topical use of tacrolimus have been relatively minor (e.g. burning, pruritus, erythema). Recently, however, the FDA reviewed the safety of topical tacrolimus, which resulted in a warning that the use of calcineurin inhibitors may be associated with an increased risk of cancer. Case presentation Oral lichen planus (OLP) was diagnosed in a 56-year-old women in February 1999. After several ineffective local and systemic therapeutic measures an off-label treatment of this recalcitrant condition using Tacrolimus 0.1% ointment was initiated in May 2002. After a few weeks of treatment most of the lesions ameliorated, with the exception of the plaques on the sides of the tongue. Nevertheless, the patient became free of symptoms which, however, reoccurred once tacrolimus was weaned, as a consequence treatment was maintained. In April 2005, the plaques on the left side of the tongue appeared increasingly compact and a biopsy specimen confirmed the suspected diagnosis of an oral squamous cell carcinoma. Conclusion The suspected causal relationship between topical use of tacrolimus and the development of a squamous cell carcinoma prompted us to test the notion that the carcinogenicity of tacrolimus may go beyond mere immune suppression. To this end, tacrolimus has been shown to have an impact on cancer signalling pathways such as the MAPK and the p53 pathway. In the given case, we were able to demonstrate that these pathways had also been altered subsequent to tacrolimus therapy." @default.
• W1805348119 created "2016-06-24" @default.
• W1805348119 creator A5021946082 @default.
• W1805348119 creator A5067045121 @default.
• W1805348119 creator A5072510059 @default.
• W1805348119 creator A5079355712 @default.
• W1805348119 date "2006-01-11" @default.
• W1805348119 modified "2023-10-16" @default.
• W1805348119 title "The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report" @default.
• W1805348119 cites W1895452036 @default.
• W1805348119 cites W1906787947 @default.
• W1805348119 cites W1970778758 @default.
• W1805348119 cites W1984506820 @default.
• W1805348119 cites W1991393598 @default.
• W1805348119 cites W2003298230 @default.
• W1805348119 cites W2003360767 @default.
• W1805348119 cites W2006581393 @default.
• W1805348119 cites W2020647833 @default.
• W1805348119 cites W2022410300 @default.
• W1805348119 cites W2023751867 @default.
• W1805348119 cites W2024996063 @default.
• W1805348119 cites W2034516258 @default.
• W1805348119 cites W2048701334 @default.
• W1805348119 cites W2052178968 @default.
• W1805348119 cites W2053317343 @default.
• W1805348119 cites W2063839793 @default.
• W1805348119 cites W2101919979 @default.
• W1805348119 cites W2105102211 @default.
• W1805348119 cites W2114862870 @default.
• W1805348119 cites W2119395460 @default.
• W1805348119 cites W2132084866 @default.
• W1805348119 cites W3025075911 @default.
• W1805348119 cites W4301780092 @default.
• W1805348119 doi "https://doi.org/10.1186/1471-2407-6-7" @default.
• W1805348119 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1386691" @default.
• W1805348119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16405733" @default.
• W1805348119 hasPublicationYear "2006" @default.
• W1805348119 type Work @default.
• W1805348119 sameAs 1805348119 @default.
• W1805348119 citedByCount "115" @default.
• W1805348119 countsByYear W18053481192012 @default.
• W1805348119 countsByYear W18053481192013 @default.
• W1805348119 countsByYear W18053481192014 @default.
• W1805348119 countsByYear W18053481192015 @default.
• W1805348119 countsByYear W18053481192016 @default.
• W1805348119 countsByYear W18053481192017 @default.
• W1805348119 countsByYear W18053481192018 @default.
• W1805348119 countsByYear W18053481192019 @default.
• W1805348119 countsByYear W18053481192020 @default.
• W1805348119 countsByYear W18053481192021 @default.
• W1805348119 countsByYear W18053481192022 @default.
• W1805348119 countsByYear W18053481192023 @default.
• W1805348119 crossrefType "journal-article" @default.
• W1805348119 hasAuthorship W1805348119A5021946082 @default.
• W1805348119 hasAuthorship W1805348119A5067045121 @default.
• W1805348119 hasAuthorship W1805348119A5072510059 @default.
• W1805348119 hasAuthorship W1805348119A5079355712 @default.
• W1805348119 hasBestOaLocation W18053481191 @default.
• W1805348119 hasConcept C121608353 @default.
• W1805348119 hasConcept C126322002 @default.
• W1805348119 hasConcept C128057223 @default.
• W1805348119 hasConcept C141071460 @default.
• W1805348119 hasConcept C142724271 @default.
• W1805348119 hasConcept C16005928 @default.
• W1805348119 hasConcept C197934379 @default.
• W1805348119 hasConcept C2776028589 @default.
• W1805348119 hasConcept C2776201145 @default.
• W1805348119 hasConcept C2778329239 @default.
• W1805348119 hasConcept C2779121184 @default.
• W1805348119 hasConcept C2779744641 @default.
• W1805348119 hasConcept C2780140570 @default.
• W1805348119 hasConcept C2909675724 @default.
• W1805348119 hasConcept C2911091166 @default.
• W1805348119 hasConcept C71924100 @default.
• W1805348119 hasConceptScore W1805348119C121608353 @default.
• W1805348119 hasConceptScore W1805348119C126322002 @default.
• W1805348119 hasConceptScore W1805348119C128057223 @default.
• W1805348119 hasConceptScore W1805348119C141071460 @default.
• W1805348119 hasConceptScore W1805348119C142724271 @default.
• W1805348119 hasConceptScore W1805348119C16005928 @default.
• W1805348119 hasConceptScore W1805348119C197934379 @default.
• W1805348119 hasConceptScore W1805348119C2776028589 @default.
• W1805348119 hasConceptScore W1805348119C2776201145 @default.
• W1805348119 hasConceptScore W1805348119C2778329239 @default.
• W1805348119 hasConceptScore W1805348119C2779121184 @default.
• W1805348119 hasConceptScore W1805348119C2779744641 @default.
• W1805348119 hasConceptScore W1805348119C2780140570 @default.
• W1805348119 hasConceptScore W1805348119C2909675724 @default.
• W1805348119 hasConceptScore W1805348119C2911091166 @default.
• W1805348119 hasConceptScore W1805348119C71924100 @default.
• W1805348119 hasIssue "1" @default.
• W1805348119 hasLocation W18053481191 @default.
• W1805348119 hasLocation W18053481192 @default.
• W1805348119 hasLocation W18053481193 @default.
• W1805348119 hasLocation W18053481194 @default.
• W1805348119 hasOpenAccess W1805348119 @default.
• W1805348119 hasPrimaryLocation W18053481191 @default.
• W1805348119 hasRelatedWork W123703021 @default.
• W1805348119 hasRelatedWork W1839380768 @default.
• W1805348119 hasRelatedWork W1982670399 @default.

• next